| Stable | Exacerbation | P value |
---|---|---|---|
Demographics | Â | Â | Â |
Age, a years | 68 ± 9 |  |  |
Gender, male (female) | 17 (19) | Â | Â |
FEV1, a % predicted | 53 ± 23 | 48 ± 19 | < 0.001 |
BMI, a (kg/m2) | 24.0 ± 6.3 |  |  |
Co Morbidities | Â | Â | Â |
Nil | 5 | Â | Â |
Gum Disease | 2 | Â | Â |
Cardiac | 30 | Â | Â |
Type 2 Diabetes | 4 | Â | Â |
Treatment | Â | Â | Â |
B2 Agonists (Short Acting) | 35 | Â | Â |
B2 Agonists (Long Acting) | 32 | Â | Â |
Anticholinergic (Short Acting) | 5 | Â | Â |
Anticholinergic (Long Acting) | 25 | Â | Â |
Inhaled Steroid | 31 | Â | Â |
Oral Theophyllines | 6 | Â | Â |
Symptom & Sputum Metricsb | Â | Â | |
Increased Cough, n | 0 | 10 | < 0.001 |
MRC Score | 5.00, 1.25 | 5.00, 1.25 | < 0.16 |
Breathing Score | 3.00, 0.00 | 4.00, 1.00 | < 0.006 |
ADL Score | 3.00, 1.00 | 4.00, 2.00 | < 0.014 |
Sputum Amount | 2.00, 2.00 | 3.00, 2.25 | < 0.001 |
Sputum Texture | 1.94, 0.33 | 2.06, 0.41 | < 0.001 |
Sputum Colour | 3.00, 1.00 | 4.00, 0.41 | < 0.05 |
Salivary Biomarkersb | Â | Â | Â |
CRP, ng/ml | 1.61, 1.10 | 7.35, 10.04 | < 0.001 |
PCT, ng/ml | 0.09, 0.06 | 0.50, 0.71 | < 0.001 |
NE, ng/ml | 128, 190 | 769, 1680 | < 0.001 |